KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- KEAP1 Gene Mutation
- NFE2L2 Gene Mutation
- Non -Small Cell Lung Cancer
- Non-Squamous Non-Small Cell Neoplasm of Lung
- Non Squamous Non Small Cell Lung Cancer
- NRF2 Gene Mutation
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Masking Description: Randomized, placebo controlledPrimary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04265534
- Collaborators
- Not Provided
- Investigators
- Study Director: Emil Kuriakose, MD Calithera Biosciences, Inc
Get Well Soon